12:26 , Oct 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Cryptosporidium Cell culture and mouse studies identified two compounds that could help treat Cryptosporidium infections. Screening of 12,000 approved or investigational compounds in a C. parvum-infected human cell line identified two compounds, VB-201 and ASP7962,...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Genentech reports ORR of 77.4% for entrectinib in pooled analysis of ROS1-positive NSCLC patients

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from an integrated analysis of 53 patients with locally advanced or metastatic c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)-positive non-small cell lung cancer (NSCLC) in...
17:06 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling TrkB fusion oncogenes and mutations could help predict sensitivity to the TrkA/TrkB/TrkC inhibitor larotrectinib in patients with blood cancers. Genomic sequencing of 7,311 patients with hematologic malignancies identified one TrkA, one TrkB and...
15:55 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Cell and rat studies identified three TrkA/TrkB/TrkC inhibitors that could help treat pain. Screening of a small molecule library in cell-based activity assays yielded three analogs of a core scaffold -- a piperidine-pyridine compound,...
01:43 , Jun 9, 2018 |  BioCentury  |  Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
01:30 , Jun 2, 2018 |  BioCentury  |  Product Development

ASCO: Pushing precision’s evolution

As the list of targeted therapies gaining approval grows, encompassing an increasingly broad spectrum of cancers, this year’s ASCO meeting aims to educate clinicians about how to determine which drugs are best in class for...
19:16 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Priority review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...
14:43 , May 29, 2018 |  BC Extra  |  Company News

Priority Review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...
22:56 , May 22, 2018 |  BC Extra  |  Tools & Techniques

Trinity identifies hurdles for tissue-agnostic therapies

While the use of basket trials to test therapies in tissue agnostic, biomarker-based cancer indications is increasing, the long-term implications rely on a handful of factors, many of which may affect postmarket uptake of agents...